Axial Biotherapeutics Co-founder Sarkis Mazmanian to Give Keynote Speech at the Microbiome in Health and Disease Keystone Symposium

Axial Biotherapeutics Co-founder Sarkis Mazmanian to Give Keynote Speech at the Microbiome in Health and Disease Keystone Symposium


BOSTON and Pasadena, Calif., February 3, 2017 – Axial Biotherapeutics, a biotechnology company building a unique class of microbial-targeted CNS therapeutics today announced that its Co-founder and California Institute of Technology (Caltech) Professor, Sarkis Mazmanian, Ph.D., will be featured as the keynote speaker at the Microbiome in Health and Disease Keystone Symposium held in Keystone, Colorado, February 5-9, 2017. The keynote titled, “The Gut-Microbiome-Brain Connection in Neurological Diseases,” will be held on Monday, February 6, 8:00 am MT / 10:00 am ET.


Dr. Mazmanian is a leader in the field of interactions between the gut microbiome and the brain as it relates to neurological disorders and Axial has licensed exclusive, worldwide rights to related intellectual property from the Mazmanian Laboratory at Caltech. Dr. Mazmanian has published his groundbreaking research in journals that include Nature, Science and Cell. Most recently, the Mazmanian Laboratory discovered a novel biological link between the gut microbiome and Parkinson’s disease (PD) published in Cell in December 2016. Axial’s focus will be to translate these discoveries into a unique class of microbial-targeted biotherapeutics that could become breakthrough therapies for a variety of neurological diseases and disorders, including Autism Spectrum Disorders (ASD) and PD.


About Axial Therapeutics


Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. Axial is advancing a pipeline of small molecule product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD), and additional preclinical initiatives in small molecules in other areas of autism and PD, as well as oncology and rare CNS diseases.


Contacts for Axial Therapeutics


Media:

Mike Beyer
Sam Brown, Inc.
312-961-2502
mikebeyer@sambrown.com


Investors:

Jeffrey Young, CFO
781-701-8467
jeffrey@axialtx.com